Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. 

 -  2019 
<br/><br/> Diffuse large B-cell lymphoma (DLBCL) is characterized by medium- to large-sized neoplastic cells that express a wide range of B-cell markers including CD19, CD20, CD22, and CD79a. Also, as this is a hematopoietic malignancy, there is expression of the leukocyte common antigen CD45. Lack of CD20 expression occurs in a specific rare heterogeneous subgroup of DLBCL including primary effusion lymphoma, plasmablastic lymphoma, ALK-positive large B-cell lymphoma, and large B-cell lymphoma arising in HHV8+ multicentric Castleman disease. In this article, we report a rare case of CD20- and CD45-negative Epstein-Barr virus-positive DLBCL in which the entities listed above were ruled out, thereby posing a significant diagnostic challenge. Arriving at the correct diagnosis of Epstein-Barr virus-positive DLBCL was supported by immunoreactivity for the B-cell transcription factor Oct-2 and the pan-B cell marker CD79a. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1066-8969 
<br/><br/><label>Standard No.: </label>10.1177/1066896918784669 [doi] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Biomarkers, Tumor/an [Analysis]<br/>*Lymphoma, Large B-Cell, Diffuse/di [Diagnosis]<br/>Adult<br/>Antigens, CD20/an [Analysis]<br/>Epstein-Barr Virus Infections/co [Complications]<br/>Herpesvirus 4, Human<br/>Humans<br/>Leukocyte Common Antigens/an [Analysis]<br/>Lymphoma, Large B-Cell, Diffuse/vi [Virology]<br/>Male
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Pathology
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article